LONZA

Lonza Group AG, a Life Sciences driven chemical company, supplies active ingredients, chemical intermediates and biotechnology solutions to the pharmaceutical and agrochemical industries. The company also offers a catalogue of organic intermediates for a range of applications, such as pharmaceuticals, agrochemicals, vitamins, food and feedstuff, dyes and pigments, adhesives and fragrances. It also manufactures specialty biocides and oleochemicals; and develops and produces specific polymer inter... mediates, unsaturated polyester-resins, compounds and composites. The company operates in three divisions that include Exclusive Synthesis & Biopharmaceuticals; Organic Fine & Performance Chemicals; and Polymer Intermediates. Exclusive Synthesis & Biopharmaceuticals In the area of Exclusive Synthesis and Biopharmaceuticals, Lonza is the custom manufacturing for the global life sciences companies. In addition to Lonza's traditional chemical custom manufacturing, Lonza offers microbial custom fermentation and biotransformation services. Lonza Biologics is focused on the production of therapeutic monoclonal antibodies and recombinant proteins produced by mammalian cell cultures. Exclusive chemical synthesis: Exclusive chemical synthesis engages in the process development and manufacture of intermediates and active ingredients. It is used in Life sciences industry, pharmaceuticals and animal health products. Exclusive microbial fermentation and biotransformation: Exclusive microbial fermentation and biotransformation processes development and manufactures intermediates, active ingredients and biopharmaceuticals. Its products are used Life sciences industry, pharmaceuticals and cosmetics. The company also offers L-Carnitine (L-Carnipure), which is applicable in sports nutrition, food, pharmaceuticals and feedstuffs. Exclusive microbial biopharma fermentation: Exclusive microbial biopharma fermentation engages in the process development and manufacture of therapeutic recombinant proteins and antibody fragments. It is used in pharmaceutical and biotechnology industry. Exclusive mammalian cell fermentation: Exclusive mammalian cell fermentation engages in the process development and manufacture of therapeutic monoclonal antibodies and recombinant proteins, proprietary GS-expression system, which are used in the pharmaceutical and biotechnology industry. Organic Fine & Performance Chemicals In the area of organic fine and performance chemicals, the company develops, manufactures, and sells various organic chemical intermediates applied in pharmaceuticals, agrochemicals, vitamins, food and feed, dyes, pigments, adhesives, and fragrances, as well as polymers. The sector performance chemical is mainly engaged in the development and production of biocides and oleochemicals. These core activities are supplemented by the polymer intermediates business, including additives, unsaturated polyester resins, compounds, and composites. Organic Fine Chemicals: The company offers Niacin, niacinamide, Diketene derivatives, Hydrocyanic acid derivatives, Engineering polymer additives and Meta รขโฌโ Metaldehyde. Its products are used in food and feedstuffs, pharmaceuticals, agrochemicals, colorants Vitamins, optical brighteners, agrochemicals, electronics, aerospace industry, and coating Snail. Performance Chemicals: The company offers microbiologically active substances, such as Quaternary ammonium, compounds, Halogenated hydantoins; and Hydantoin derivatives. It also offers Oleochemical derivatives. The company's products are used by the disinfectants for household, industrial and institutional applications, including water treatment and wood preservation; biocides for water treatment, pools and spas, and household disinfection; preservatives for personal care and household products; and food ingredients, humectants and emollients for personal care, processing aids and lubricants for polymer and textile industry, and industrial defoamers.
LONZA
Industry:
Biotechnology Life Science Pharmaceutical
Founded:
1897-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.lonza.com
Total Employee:
10001+
Status:
Active
Contact:
00041 61 316 81 11
Email Addresses:
[email protected]
Technology used in webpage:
LetsEncrypt Apple Mobile Web Clips Icon Domain Not Resolving Apache Mobile Non Scaleable Content IPv6 AJAX Libraries API Google Google Cloud Cloudflare Hosting
Similar Organizations
Lek d.d.
Lek d.d. develops, produces, and distributes generics pharmaceuticals for customers worldwide.
Michrom Bioresources
Michrom Bioresources supplies microfluidic products.
Pierrel S.p.A
Pierrel S.p.A is a global service provider for the pharmaceutical, bio-pharmaceutical and life science industries.
ProsCon Ltd
ProsCon Ltd is primarily serves major customers in the pharmaceutical and biotechnology markets.
Leadiant Biosciences
Leadiant Biosciences is a pharmaceutical company dedicated to the development, registration and commercialization of effective therapies.
Current Advisors List
Current Employees Featured
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2021-11-02 | Codiak Biosciences | Codiak Biosciences acquired by Lonza | 65 M USD |
2018-10-29 | Octane Biotech | Octane Biotech acquired by Lonza | N/A |
2017-08-04 | Micromacinazione | Micromacinazione acquired by Lonza | N/A |
2017-05-30 | PharmaCell | PharmaCell acquired by Lonza | N/A |
2017-05-16 | HansaBioMed | HansaBioMed acquired by Lonza | N/A |
2016-12-12 | Capsugel | Capsugel acquired by Lonza | 5.5 B USD |
2016-08-15 | InterHealth Nutraceuticals | InterHealth Nutraceuticals acquired by Lonza | 300 M USD |
2016-06-30 | Triangle Research Labs | Triangle Research Labs acquired by Lonza | N/A |
2015-11-01 | Diacon Technologies Ltd. | Diacon Technologies Ltd. acquired by Lonza | N/A |
2015-08-03 | Zelam | Zelam acquired by Lonza | N/A |
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2022-02-10 | Indapta Therapeutics | Lonza investment in Series A - Indapta Therapeutics | 50 M USD |
2021-05-03 | Affinia Therapeutics | Lonza investment in Series B - Affinia Therapeutics | 110 M USD |
2020-03-31 | Affinia Therapeutics | Lonza investment in Series A - Affinia Therapeutics | 60 M USD |
2017-05-16 | Exosomics Siena | Lonza investment in Funding Round - Exosomics Siena | N/A |
2016-12-02 | ConnectedYard (pHin) | Lonza investment in Series A - ConnectedYard (pHin) | 7 M USD |
2013-02-14 | Odyssey Thera | Lonza investment in Venture Round - Odyssey Thera | 2.8 M USD |
2009-10-22 | Cilian AG | Lonza investment in Corporate Round - Cilian AG | N/A |
Newest Events participated



Key Employee Changes
Official Site Inspections
http://www.lonza.com
- Host name: 51.144.88.178
- IP address: 51.144.88.178
- Location: Amsterdam Netherlands
- Latitude: 52.3534
- Longitude: 4.9087
- Timezone: Europe/Amsterdam
- Postal: 1091

More informations about "Lonza"
About Us - Lonza
Lonza is one of the worldโs largest contract development and manufacturing organizations (CDMOs), dedicated to serving the healthcare industry. We work alongside a broad range of โฆSee details»
Leadership - Lonza
As a global organization, Lonza is focused on achieving the strategic vision of being the world's leading integrated solutions provider for its pharma and consumer healthcare and nutrition โฆSee details»
Lonza - The Org
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial โฆSee details»
Lonza Investor Update 2024 Outlines Strategy, New Organizational ...
Dec 12, 2024 Lonza Group Ltd | Muenchensteinerstrasse 38 | CH-4002 Basel | Switzerland +41 (0) 61 316 81 11 | www.lonza.com | [email protected] 1 / 4 Lonza Investor Update 2024 โฆSee details»
Lonza Announces New Organizational Structure for CDMO โฆ
Jan 2, 2025 Lonza has announced a new organization structure for its CDMO business and announced it plans to exit its Capsules & Health Ingredients business. The company made the โฆSee details»
Lonza Org Chart + Executive Team - The Official Board
Mar 14, 2025 The org chart of Lonza contains its 36 main executives like Wolfgang Wienand, Philippe Deecke and Ulrich Osswald.See details»
Lonza - Crunchbase Company Profile & Funding
Lonza provides integrated solutions for parenteral drug development, addressing formulation, process design, and primary packaging for clinical and commercial supply. mRNA / LNP Services: Lonza supports mRNA and lipid nanoparticle โฆSee details»
Lonza - Leadership Team - The Org
The Leadership Team at Lonza is responsible for setting the strategic direction and ensuring the operational excellence of the company across its various divisions. Comprising executives โฆSee details»
Lonza Initiates New Organizational Structure
Apr 3, 2025 Lonza has begun the implementation of its previously announced new organization structure for its CDMO business.. The moves are part of an overall company strategy for a โฆSee details»
Our Strategy - Lonza
At Lonza, we have a vision to be the pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology and lean manufacturing. At the heart of our approach is the One Lonza strategy, โฆSee details»
Lonza Outlines Restructuring Strategy and New Organizational โฆ
Lonza also wants to analyze the possibility of bolt-on mergers and acquisitions (bolt-on M&A) and take an unbiased view of organic and inorganic opportunities for future growth. Lonza CEO โฆSee details»
Lonza Streamlines Organizational Structure - Morningstar
Dec 12, 2024 By Andrea Figueras . Lonza said it will focus on its core contract development and manufacturing organization business as it launches a restructuring to boost growth and โฆSee details»
Lonza confirms full-year outlook as it does not expect โmaterial ...
1 day ago Investing.com -- Lonza Group AG (SIX: LONN) said Friday it doesnโt foresee a significant financial hit from potential tariffs and reaffirmed its full-year outlook for its contract โฆSee details»
Lonza Management Team | Org Chart - RocketReach
Lonza employs 17,760 employees. The Lonza management team includes Pierre-Alain Ruffieux (Chief Operating Officer), Annie Lim (Head of Human Resources), and Albert Pereda โฆSee details»
Lonza Investor Update 2024 Outlines Strategy, New Organizational ...
Dec 12, 2024 Lonza has provided an overview of its new โOne Lonzaโ strategy and new organizational structure; As Lonza focuses on its core CDMO 1 business, it will exit the โฆSee details»
Lonza AG - Swiss Biotech
Lonza is a global partner to the pharmaceutical, biotech and nutrition markets. By combining technological insight with world-class manufacturing, scientific expertise and process โฆSee details»
Lonza Group AG (LZAGY) Q1 2025 Earnings Call Transcript
Lonza Group AG (OTCPK:LZAGY) Q1 2025 Earnings Conference Call May 9, 2025 9:00 AM ET. Company Participants. ... The setup will provide us with a more scalable organization, improve โฆSee details»
Lonza | Governance
Dec 31, 2024 The principles and rules of Lonzaโs corporate governance are laid down in the Lonza Articles of Association and in the Regulations Governing Internal Organization and โฆSee details»
Lonza bevestigt sterke vooruitzichten voor 2025 in eerste kwartaal
1 day ago Lonza Group AG (LONN) heeft zijn robuuste vooruitzichten voor 2025 herbevestigd, met een verwachte significante groei in zijn Contract Development and Manufacturing โฆSee details»
Lonza : bien orienté après un point trimestriel | Zonebourse
1 day ago Lonza prend près de 4% à Zurich, salué pour un point d'activité du groupe de services à l'industrie pharmaceutique, qui revendique 'de solides performances dans toutes les activités ...See details»